Skip to main content
. 2022 Apr 1;12:865121. doi: 10.3389/fonc.2022.865121

Table 1.

Comparison of clinical indices and pathological data between NAC non-effectual group and NAC effectual group.

Characteristics NAC non-effectual group n = 5 NAC effectual group n = 18 p-value
Age (years, mean ± SD) 52.80 ± 7.16 50.50 ± 10.41 0.58
BMI (kg/m2, mean ± SD) 21.99 ± 3.10 22.74 ± 3.20 0.65
Menopausal status Premenopausal 2 10 0.64
Postmenopausal 3 8
Pathological Type (tumor size) IDC 5 17 1.00
LDC 0 1
T stage T1-T2 3 13 0.62
T3-T4 2 5
N stage N0-N1 4 16 0.54
N2-N3 1 2
Histologic grade Period II A-II B 3 11 1.00
Period III A-III C 2 7
ER expression Positive 4 12 1.00
Negative 1 6
PR expression Positive 3 6 0.34
Negative 2 12
HER2 expression 0-2+ 5 10 0.12
3+ 0 8
Ki-67 expression ≥20% 3 13 0.62
<20% 2 5
Blood TILs ratio (%, mean ± SD)
CD3+TILs 69.34 ± 9.25 73.78 ± 8.63 0.23
CD4+TILs 36.12 ± 3.95 41.39 ± 6.94 0.04
CD8+TILs 23.92 ± 3.39 24.60 ± 6.37 1.00
CD4+/CD8+TILs 1.54 ± 0.35 1.77 ± 0.42 0.22
Therapy
Cyclophosphamide-containing chemotherapy regimen Yes 5 18 /
No 0 0
Anthracycline-containing chemotherapy Yes 3 12 1.000
No 2 6
Taxol-containing chemotherapy Yes 4 14 1.000
No 1 4
Herceptin targeted therapy Yes 5 10 0.12
No 0 8
Chemotherapy cycle ≤6 cycles 4 14 1.000
>6 cycles 1 4
Chemotherapy interval Intensive chemotherapy 1 3 1.000
Conventional chemotherapy 4 15

IDC, invasive ductal carcinoma; LDC, invasive lobular carcinoma; TILs, tumor infiltrating lymphocytes.

Tumors were categorized as ER, PR, HER2, and Ki-67 based on immunohistochemical testing results. If HER2 immunohistochemical testing result is 2+, two-probe method FISH is required.

Bolded values indicate the significant results.